Kai Wang, Chengying Kong, Jingnan Zhang, Li Sun, Qijia Xuan, Haining Huang. "A first-in-human (FIH), phase I/II open-label, dose-escalation and -expansion study of ILKN421H, an LNP mRNA encoding an IL2Rβγ selective IL-2v, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.8556